Literature DB >> 353597

The treatment of hypertension with verapamil.

G R Lewis, K D Morley, B M Lewis, P J Bones.   

Abstract

In a randomised double blind cross over trial, verapamil produced significant dose dependent reductions in blood pressure in 23 patients. There were minimal side-effects. All patients had some contraindication to the use of beta blocker therapy, and the role of verapmil in this situation is discussed.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 353597

Source DB:  PubMed          Journal:  N Z Med J        ISSN: 0028-8446


  28 in total

1.  A comparison of verapamil and nifedipine on quality of life.

Authors:  A Palmer; A Fletcher; G Hamilton; S Muriss; C Bulpitt
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

Review 2.  Calcium antagonists and their mode of action: an historical overview.

Authors:  W G Nayler; J S Dillon
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

3.  Sustained release verapamil in renal hypertension.

Authors:  H Eiskjaer; E B Pedersen; L M Rasmussen; B Jespersen
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 4.  The management of hypertension.

Authors:  B N Prichard; C W Owens
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

Review 5.  Studies on verapamil in the treatment of essential hypertension: a review.

Authors:  K Midtbø; O Hals; O Lauve; J van der Meer; L Storstein
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

6.  Nicardipine hydrochloride in essential hypertension--a controlled study.

Authors:  J Asplund
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

7.  Relative potency of a beta-blocking and a calcium entry blocking agent as antihypertensive drugs in black patients.

Authors:  J R M'Buyamba-Kabangu; B Lepira; R Fagard; P Lijnen; M Ditu; K A Tshiani; A Amery
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin.

Authors:  Dong-Hyun Choi; Joong-Hwa Chung; Jun-Shik Choi
Journal:  Eur J Clin Pharmacol       Date:  2009-12-12       Impact factor: 2.953

9.  Sustained release verapamil in hypertension. Results from a noninvasive ambulatory blood pressure monitoring and a clinical study.

Authors:  A Nissinen; A Koistinen; J Tuomilehto; S Sundberg; A Gordin
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

10.  Assessment of 'once daily' verapamil for the treatment of hypertension using ambulatory, intra-arterial blood pressure recording.

Authors:  M Caruana; M Heber; G Brigden; E B Raftery
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.